Is PTHS (PTHS) Halal?

AMEX Healthcare United States $75M
✓ HALAL
Confidence: 95/100
PTHS (PTHS) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 2.9% against the AAOIFI threshold of 30%, PTHS comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Biotechnology), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 2.9%
/ 30%
0.7%
/ 30%
0.1%
/ 30%
N/A ✓ HALAL
DJIM 2.9%
/ 33%
0.7%
/ 33%
0.1%
/ 33%
N/A ✓ HALAL
MSCI 159.7%
/ 33%
37.5%
/ 33%
3.0%
/ 33%
N/A ✗ NOT HALAL
S&P 2.9%
/ 33%
0.7%
/ 33%
0.1%
/ 33%
N/A ✓ HALAL
FTSE 159.7%
/ 33%
37.5%
/ 33%
3.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-23.04
P/B Ratio
1.9
EV/EBITDA
-3.2
EV: $92M
Revenue
$0
Beta
3.9
High volatility
Current Ratio
2.1

Profitability

Gross Margin 68.9%
Operating Margin -127.8%
Net Margin -257.9%
Return on Equity (ROE) -239.6%
Return on Assets (ROA) -29.8%

Cash Flow & Balance Sheet

Operating Cash Flow-$6M
Free Cash Flow-$6M
Total Debt$2M
Debt-to-Equity89.6
Current Ratio2.1
Total Assets$1M

Price & Trading

Last Close$22.74
50-Day MA$23.24
200-Day MA$24.82
Avg Volume11K
Beta3.9
52-Week Range
$9.00
$54.29

About PTHS (PTHS)

CEO
Mr. Scott M. Plesha
Employees
92
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
AMEX
Market Cap
$75M
Currency
USD

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is PTHS (PTHS) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), PTHS is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is PTHS's debt ratio?

PTHS's debt ratio is 2.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 159.7%.

What are PTHS's key financial metrics?

PTHS has a market capitalization of $75M. The company maintains a gross margin of 68.9% and a net margin of -257.9%. Return on equity stands at -239.6%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.